Sentences with phrase «myxomatous mitral»

Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.

Interventional Cardiology, Diagnosis and Treatment of Myocarditis, Myxomatous Mitral Valve Disease, and Cardiac Biomarkers

16 Tidholm A, Ljungvall I, Hoglund AB, Westling AB, Haggstrom J. Tissue Doppler and Strain Imaging in Dogs with Myxomatous Mitral Valve Disease in Different Stages of Congestive Heart Failure.

Mitral regurgitation (MR), secondary to myxomatous mitral valve disease (MMVD), is the most common cardiac disorder in dogs and is usually caused by progressive degeneration of the atrioventricular valves.

Overview Myxomatous mitral valve degeneration (MMVD) is the most common acquired type of heart disease and new murmurs in older dogs.

The licence for Vetmedin (Boehringer Ingelheim) has been extended to cover dogs with asymptomatic myxomatous mitral valve disease (MMVD).

The trial, titled «Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease (MMVD) and Cardiomegaly» (EPIC), is the largest clinical study ever to be conducted in veterinary cardiology.

Currently, there are active research programs involving management of congestive heart failure, myxomatous mitral valve disease, feline cardiomyopathy, thrombosis and antithrombotic therapy, pacemaker therapy, and correction of congenital cardiac disease.

Heart Mitral Valve Disease (MVD), or more correctly, myxomatous mitral valve disease (MMVD) is the leading cause of death of Cavalier King Charles Spaniels throughout the world.

Parker, H. G. and Kilroy - Glynn, P. (1016), Myxomatous mitral valve disease in dogs: Does size matter?

AKC / CHF GRANT # 00908: Serotonin Type2A Receptor Antagonist Therapy for Preventing the Progression of Myxomatous Mitral Valve Disease.

«Left Atrial Rupture Secondary to Myxomatous Mitral Valve Disease in 11 dogs.»

Large and giant breeds of dog typically do not suffer from myxomatous mitral valve disease to the same extent as smaller dogs.

The disease which causes the thickening and distortion of the mitral valve is known as myxomatous mitral valve disease and we will talk about this common condition some more in future articles.

The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD).

The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary endpoint).

His research interests include interventional cardiology, diagnosis and treatment of myocarditis, myxomatous mitral valve disease and cardiac biomarkers.

This groundbreaking study sought to answer a key question: Can pimobendan — with proven efficacy in treating dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)-- also delay the onset of CHF caused by MMVD?

The EPIC Study showed a significant benefit in administering pimobendan in dogs with preclinical myxomatous mitral valve disease (MMVD)-- before the onset of congestive heart failure (CHF) cardiac - related death, or euthanasia (composite primary endpoint).

To ensure a homogenous group of dogs and because myxomatous mitral valve disease (MMVD) most commonly affects dogs within this weight range (4.1 — 15 kg, or 9 — 33.1 lbs)

There is currently no treatment licensed for the management of preclinical myxomatous mitral valve disease (MMVD).

Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study - a randomized clinical trial.

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study — A Randomized Clinical Trial.

In the VetSCOPE Study, pimobendan rapidly improved the quality of life in dogs with CHF caused by myxomatous mitral valve disease (MMVD).

Echocardiographic evidence of myxomatous mitral valve disease (MMVD) defined as characteristic valvular lesions of the mitral valve apparatus

The following simple screening process has been developed to help you determine whether dogs suspected to have myxomatous mitral valve disease (MMVD) have evidence of disease progression.

To determine whether chronic oral administration of pimobendan in dogs with evidence of increased heart size secondary to preclinical myxomatous mitral valve disease (MMVD) can delay the onset of clinical signs of congestive heart failure (CHF).1

Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST Study.

In the QUEST Study, pimobendan significantly increased the survival time of dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD).

Not exact matches

the location of myxomatous nodules at the tip of the mitral leaflets.

Echocardiographic dimensions of 20 dogs with myxomatous degeneration of the mitral valve were compared in this paper.

Representative photomicrographs of mitral valve myxomatous degeneration showing: endothelial loss and increased endothelial

- SMA), embryonic smooth muscle myosin (Smemb) and vimentin in mitral valve myxomatous degeneration.

Myxomatous degeneration of the mitral valve (MMVD) accounts for nearly 75 percent of all heart problems seen by veterinarians, making it the most common heart disease diagnosed in dogs.